Physician profile
Devinder Bhrany
NPI 1144225137
$6,783.98
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $1,953 · 2021: $2,174 · 2022: $1,203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $802.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $660.62 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $613.77 | 2019-2022 | |
| Amgen INC. | $478.57 | 2019-2022 | |
| Abbvie INC. | $436.35 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $403.88 | 2019-2022 | |
| Eisai INC. | $323.33 | 2019-2022 | |
| Mdd US Operations, LLC | $304.90 | 2019-2020 | |
| Genzyme Corporation | $230.62 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $188.00 | 2020-2022 | |
| Celgene Corporation | $182.74 | 2021 | |
| Neurocrine Biosciences, INC. | $174.00 | 2019-2021 | |
| Allergan, INC. | $166.75 | 2020 | |
| Neurelis, INC. | $154.77 | 2020-2022 | |
| Acorda Therapeutics, INC | $141.48 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $141.39 | 2019-2020 | |
| Ucb, INC. | $127.57 | 2021 | |
| Kyowa Kirin, INC. | $125.81 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $113.46 | 2020-2022 | |
| Emd Serono, INC. | $111.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $96.24 | 2020-2021 | |
| Lundbeck LLC | $88.68 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $84.47 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $71.39 | 2022 | |
| Horizon Therapeutics Plc | $65.77 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $61.48 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $47.17 | 2019 | |
| Tanabe Pharma America, INC. | $42.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $42.27 | 2020-2021 | |
| Sk Life Science, INC. | $36.28 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $34.34 | 2021 | |
| Mallinckrodt Hospital Products INC. | $33.86 | 2021 | |
| Genentech USA, INC. | $33.03 | 2019 | |
| Zyla Life Sciences, INC. | $32.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $30.46 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $26.45 | 2021 | |
| Adamas Pharmaceuticals, INC. | $22.33 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.26 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devinder Bhrany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.